Jasper Therapeutics (JSPR)
(Real Time Quote from BATS)
$22.73 USD
-0.24 (-1.05%)
Updated Sep 18, 2024 01:16 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Jasper Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 69 | 51 | 37 | 1 | 0 |
Income After Depreciation & Amortization | -69 | -51 | -37 | -1 | 0 |
Non-Operating Income | 4 | 14 | 6 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -64 | -38 | -31 | -1 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -64 | -38 | -31 | -1 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -64 | -38 | -31 | -1 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -68 | -50 | -36 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -69 | -51 | -37 | -1 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 10.44 | 3.65 | 1.14 | NA | NA |
Diluted EPS Before Non-Recurring Items | -6.18 | -10.30 | -32.40 | NA | NA |
Diluted Net EPS (GAAP) | -6.18 | -10.30 | -26.90 | -2.40 | NA |
Fiscal Year end for Jasper Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 16.00 | 15.07 | 17.73 | 19.36 | 17.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | -16.00 | -15.07 | -17.73 | -19.36 | -17.83 |
Non-Operating Income | 1.41 | 1.34 | 1.14 | 1.82 | 1.75 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -14.58 | -13.73 | -16.58 | -17.54 | -16.08 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -14.58 | -13.73 | -16.58 | -17.54 | -16.08 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -14.58 | -13.73 | -16.58 | -17.54 | -16.08 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 14.99 | 13.34 | 11.05 | 10.97 | 10.92 |
Diluted EPS Before Non-Recurring Items | -0.97 | -1.03 | -1.50 | -1.60 | -1.50 |
Diluted Net EPS (GAAP) | -0.97 | -1.03 | -1.48 | -1.60 | -1.50 |